|Committee Member||Employment||Consultant||Speakers Bureau||Ownership/Partnership/Principal||Personal Research||Institutional, Organizational, or Other Financial Benefit||Expert Witness|
|Clyde W. Yancy (Chair)||Northwestern University, Feinberg School of Medicine—Vice Dean, Diversity & Inclusion; Magerstadt Professor of Medicine; Chief, Division of Cardiology||None||None||None||None||None||None|
|James L. Januzzi Jr. (Vice Chair)||Massachusetts General Hospital—Professor of Medicine, Harvard Medical School||None||None||None||None|
|Larry A. Allen||University of Colorado School of Medicine—Associate Professor of Medicine||None||None||None||None|
|Javed Butler||Stony Brook University School of Medicine—Professor of Medicine||None||None|
|Leslie L. Davis||University of North Carolina, Greensboro—Associate Professor of Nursing||None||None||None||None||None||None|
|Gregg C. Fonarow||David Geffen School of Medicine, UCLA Division of Cardiology—Professor of Medicine||None||None||None||None|
|Nasrien E. Ibrahim||Massachusetts General Hospital—Clinical Research Fellow||None||None||None||None||None|
|Mariell Jessup||Fondation Leducq—Chief Scientific Officer||None||None||None||None||None||None|
|JoAnn Lindenfeld||Vanderbilt University—Director, Heart Failure and Transplantation Program||None||None||None|
|Thomas M. Maddox||BJC Healthcare/WashingtonUniversity School of Medicine--Director, Health Systems Innovation Lab; Professor of Medicine (Cardiology)||None||None||None||None||None||None|
|Frederick A. Masoudi||University of Colorado Anschutz Medical Campus—Professor of Medicine||None||None||None||None||None||None|
|Shweta R. Motiwala||Beth Israel Deaconess Medical Center—Instructor of Medicine, Harvard Medical School||None||None||None||None||None||None|
|J. Herbert Patterson||UNC Eshelman School of Pharmacy—Professor of Pharmacy and Research; Professor of Medicine||None||None||None||None|
|Mary Norine Walsh||St. Vincent Heart Center—Medical Director, Heart Failure and Cardiac Transplantation||None||None||None||None||None||None|
|Alan Wasserman||The George Washington University School of Medicine and Health Sciences—Eugene Meyer Professor of Medicine; Chairman, Department of Medicine||None||None||None||None||None||None|
This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.
According to the ACC, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document or makes a competing drug or device addressed in the document; or c) the person or a member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.
CEC = Clinical Events Committee; DSMB = Data Safety Monitoring Board; JACC = Journal of the American College of Cardiology.